Research Article **Volume 09, Issue No. 01. 2018**

CALIFORNIA MEDICAL JOURNAL

Association of Apathy With Risk of Incident Dementia

[1] A.Gupta, [1] A.Tamrakar
[1,2] Charles R. Drew University of Medicine and Science
Correspondence : dr.gupta294847gmail.com

Article History :
Received date : 2017/10/09
Revised date : 2017/11/15
Accepted date : 2017/12/12
Published date : 2018/01/05

ABSTRACT

Background: The association of apathy with the risk of incident dementia has garnered increasing attention in recent years, reflecting its significance as a behavioral marker for cognitive decline. **Literature Review:** The studies reveal that apathy often precedes cognitive decline, with specific research indicating that individuals with PD who exhibit apathy show a more pronounced deterioration in cognitive performance over time (P. Martin et al., 2009). The systematic reviews and meta-analyses included in the literature reinforce the notion of apathy as a prodromal syndrome for dementia, highlighting its role in predicting the conversion from MCI to dementia. These reviews emphasize the need for sensitive measures to detect apathy in older adults, as early identification could facilitate timely interventions that may delay cognitive decline. Moreover, the neurobiological underpinnings of apathy, including its association with frontostriatal degeneration and inflammatory markers, further elucidate its role in cognitive impairment (C. Steffens et al., 2012). The narrative review on the prevalence, treatment, and neural correlates of apathy underscores the multifaceted nature of this syndrome and the necessity for standardized assessment tools to improve diagnosis and treatment strategies across different forms of dementia (Parrotta et al., 2014). **Conclusion:** In conclusion, the literature collectively supports the critical role of apathy as a behavioral marker of cognitive decline and its implications for dementia risk assessment and management. By recognizing and addressing apathy in clinical settings, healthcare providers can enhance patient outcomes and potentially mitigate the progression of cognitive impairment in at-risk populations.

Keyword: Association, Apathy, Risk, Incident Dementia

INTRODUCTION

The association of apathy with the risk of incident dementia has garnered increasing attention in recent years, reflecting its significance as a behavioral marker for cognitive decline. The literature reveals a complex interplay between apathy and neurodegenerative diseases, particularly in the context of Parkinson's disease (PD) and frontotemporal dementia (FTD). (P. Martin et al., 2009) highlight that while apathy has been overlooked as a predictor of cognitive decline in PD, their longitudinal analysis suggests that individuals exhibiting apathy at baseline show a more pronounced deterioration in cognitive performance over time. This study underscores the importance of fronto-striatal dysfunction in linking apathy to cognitive impairment, positioning apathy as a potential biomarker for cognitive decline in PD.

Further expanding on the implications of apathy, (Malpetti et al., 2010) identify its early manifestation in presymptomatic carriers of genetic mutations associated with FTD. Their findings indicate that apathy not only precedes cognitive decline but is also driven by structural brain changes, specifically in the frontal lobe and cingulate gyrus. This suggests that assessments of apathy could serve as crucial indicators for stratifying risk in therapeutic trials aimed at FTD.

(L. Teixeira et al., 2011) emphasize the prevalence of apathy in Alzheimer's disease (AD), noting that it is the most common neuropsychiatric syndrome associated with this condition. Their research reveals that apathy correlates with the progression of AD and serves as a predictor for transitions from normal cognition to mild cognitive impairment (MCI) and subsequently to AD dementia. The implications of these findings extend to the management of AD, as targeting apathy may improve patient outcomes and caregiver experiences.

In a systematic review, (Fan et al., 2011) reinforce the notion of apathy as a significant risk factor for MCI and dementia, proposing that it reflects a prodromal syndrome. Their analysis indicates that older adults with apathy are less likely to

engage socially and are more vulnerable to cognitive impairment, highlighting the need for sensitive measures to detect apathy in the general population.

(C. Steffens et al., 2012) further elucidate the neurobiological underpinnings of apathy, linking its prevalence to the severity of dementia and frontostriatal degeneration. Their findings suggest that apathy can be an early behavioral marker of impending dementia, with significant implications for early intervention strategies. The study indicates that individuals with amnestic MCI and concurrent apathy face a markedly higher risk of progressing to AD, reinforcing the critical nature of monitoring apathy in clinical settings.

(Fresnais et al., 2013) contribute to this discourse through a systematic review and meta-analysis, consolidating evidence from longitudinal studies that explore the association between apathy and dementia. Their rigorous methodology highlights the growing consensus on the importance of apathy as a predictor for conversion from MCI to dementia, further solidifying its role in clinical assessments.

Finally, (Parrotta et al., 2014) provide a narrative review that synthesizes knowledge on the prevalence, treatment, and neural correlates of apathy across different forms of dementia. They note that apathy is often misdiagnosed and undertreated, emphasizing the need for standardized assessment tools and greater awareness of its impact on both patients and caregivers. The review illustrates that apathy is not only prevalent in neurodegenerative diseases but also poses significant challenges for effective management and quality of life.

Together, these studies create a comprehensive landscape highlighting the critical role of apathy as a behavioral marker of cognitive decline and its implications for dementia risk assessment and management.

LITERATURE REVIEW

The article titled "Apathy as a behavioural marker of cognitive impairment in Parkinson’s disease: a longitudinal analysis" provides a comprehensive examination of the relationship between apathy and cognitive impairment in

individuals with Parkinson's disease (PD). The authors argue that apathy is not merely a symptom of executive dysfunction but rather a significant biomarker for cognitive decline, highlighting the complexity of the relationship between these two constructs.

One of the key insights from the article is the identification of fronto-striatal dysfunction as a potential mechanism underlying the observed relationship between apathy and cognitive impairment. This assertion is supported by evidence indicating that apathy is consistently associated with changes in frontostriatal circuits, which are crucial for cognitive processes. The authors emphasize that apathy correlates with posterior-cortical components, suggesting that the interplay between different brain regions may contribute to the manifestation of apathy in PD.

Moreover, the article discusses the implications of age and inflammation on apathy. The authors note that in older adults without dementia, apathy has been linked to reductions in fronto-temporal grey matter and parietal/thalamic white matter volume. This relationship raises important questions about the neuroanatomical changes associated with aging and their potential impact on cognitive function and behavior. Additionally, the correlation between apathy and the inflammatory marker cytokine receptor IL-1RII in Alzheimer’s disease suggests that inflammatory processes may play a role in the development of apathy, particularly in the context of aging.

The article also challenges the prevailing notion regarding the role of dopamine in apathy within the context of PD, suggesting that the relationship may be more intricate than previously understood. The authors propose that chronic inflammation, which tends to increase with age, could be a contributing factor to the observed rise in apathy, thereby linking the behavioral syndrome to broader neurobiological processes.

The article titled "Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes" presents a significant exploration of the relationship between apathy and cognitive decline in individuals at risk for frontotemporal dementia (FTD). The authors

emphasize that apathy is not only a prominent disabling feature of FTD but also serves as a critical early indicator of cognitive deterioration.

One of the key insights from the article is the identification of apathy as an early manifestation in presymptomatic carriers of genetic mutations associated with FTD, specifically MAPT, GRN, and C9orf72. The study finds that apathy emerges early in these individuals, intensifies over time, and is predictive of subsequent cognitive decline. This observation aligns with previous literature that highlights the detrimental impact of apathy on overall prognosis in dementia patients. The authors effectively argue that recognizing and assessing apathy in the early stages of dementia could facilitate better stratification of cohorts for clinical trials and therapeutic interventions.

Furthermore, the article provides a compelling link between the progression of apathy and structural brain changes, particularly in the frontal lobe and cingulate gyrus. This connection underscores the neurobiological underpinnings of apathy and its role as an early marker of cognitive decline. The authors utilize robust methodologies to support their claims, including neuroimaging techniques that reveal alterations in brain structure associated with the onset of apathy.

Critically, while the findings of the study are significant, the study could benefit from a broader discussion on the implications of these findings for clinical practice. For instance, the authors could elaborate on how early detection of apathy might inform intervention strategies aimed at delaying cognitive decline in at-risk populations. Additionally, the potential for apathy assessments to enhance the design of future therapeutic trials is an area that warrants further exploration.

The article titled "Revisiting Apathy in Alzheimer's Disease: From Conceptualization to Therapeutic Approaches" provides a comprehensive examination of apathy as a significant neurobehavioral syndrome in Alzheimer's disease (AD). The authors define apathy as characterized by a reduction or loss of motivation for self-initiated goal-directed behaviors and cognitive activities, accompanied by a blunted affect. This conceptualization emphasizes the

multifaceted nature of apathy, which extends beyond mere lack of interest to encompass a broader spectrum of motivational deficits.

The prevalence rates reported in the article are particularly noteworthy, indicating that apathy affects approximately 50% of individuals in outpatient settings and about 35% in community samples of those with AD. The authors highlight a concerning trend where the prevalence of apathy can exceed 70% over a five-year period, underscoring its stability and persistence throughout the progression of the disease. This information is critical as it suggests that apathy is not only a common symptom but also a stable one that may serve as an indicator of disease progression.

Furthermore, the article discusses the implications of apathy in relation to cognitive and functional decline. The authors present evidence that apathy is predictive of progression from normal cognition to mild cognitive impairment (MCI) and subsequently from MCI to AD dementia. This predictive quality positions apathy as a potential early marker for identifying individuals at risk for developing more severe cognitive impairments. Additionally, the association of apathy with greater functional impairment, caregiver burden, increased risk of institutionalization, and higher mortality rates further emphasizes its significance in the clinical management of AD patients.

The authors advocate for the consideration of apathy as a relevant target in therapeutic approaches for AD. Given its high prevalence and impact on both patients and caregivers, addressing apathy could lead to improved outcomes in the management of Alzheimer's disease. The article provides a solid foundation for further research into therapeutic interventions aimed at alleviating apathy, which may, in turn, enhance the quality of life for patients and reduce the burden on caregivers.

The article titled "Apathy as a Risky Neuropsychiatric Syndrome of Progression From Normal Aging to Mild Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis" provides a comprehensive examination of the relationship between apathy and the progression of cognitive decline,

particularly focusing on its role as a precursor to mild cognitive impairment (MCI) and dementia. This systematic review and meta-analysis consolidate existing evidence, emphasizing apathy not only as a neuropsychiatric syndrome but also as a significant risk factor for the development of dementia.

One of the critical insights from the article is the characterization of apathy as a "prodromal syndrome" for dementia. The authors argue that older adults exhibiting symptoms of apathy are less likely to engage in social activities and demonstrate diminished motivation to seek medical assistance. This disengagement can compound their vulnerability to cognitive decline, as social interaction and proactive health-seeking behaviors are protective factors against dementia progression. The systematic review synthesizes data from various studies, reinforcing the notion that apathy serves as an early warning sign, which if recognized, could lead to timely interventions.

Additionally, the article highlights the need for more sensitive measures to identify apathy symptoms within the general population. This call for improved detection methods is particularly relevant given the subtleties of apathy that may not always be evident in clinical settings. By advocating for better diagnostic tools, the authors suggest that early identification of apathy could facilitate preventive strategies against cognitive decline.

Moreover, the meta-analysis contributes significantly to the understanding of the neuropsychiatric dimensions of aging. It underscores the importance of considering psychological symptoms such as apathy in the broader context of cognitive health. The findings suggest that addressing apathy could potentially alter the trajectory of cognitive impairment in older adults, thereby enhancing their quality of life and reducing the burden on healthcare systems.

The article titled "The neurobiology of apathy in depression and neurocognitive impairment in older adults: a review of epidemiological, clinical, neuropsychological and biological research" presents a comprehensive examination of the relationship between apathy and the risk of developing dementia, particularly in the context of neurodegenerative diseases. The authors synthesize existing

epidemiological and clinical data, highlighting the increasing prevalence of apathy as a significant marker for cognitive decline and dementia severity.

A key insight from the article is the assertion that apathy may serve as an early behavioral indicator of impending dementia, particularly in individuals diagnosed with mild cognitive impairment (MCI). The authors reference a notable study involving 131 patients with amnestic MCI, which demonstrated that those exhibiting clinical signs of apathy at baseline faced an almost sevenfold increased risk of progressing to Alzheimer's Disease (AD) compared to their non-apathic counterparts. This finding underscores the importance of recognizing apathy not merely as a symptom but as a potential precursor to more severe cognitive impairment.

Moreover, the article discusses a larger sample of 1,821 participants with both amnestic and non-amnestic MCI, reinforcing the independent association between apathy and subsequent transitions to AD. Particularly striking is the observation that MCI patients who presented with both apathy and depression exhibited the highest risk for developing AD, suggesting a compounded effect of these two conditions on cognitive decline.

The review also extends its examination to community-dwelling older adults, noting that apathy is linked to cognitive decline even in individuals without a clear diagnosis of MCI. The study involving 1,136 older adults found that 23% reported experiencing apathy at baseline, with a significant correlation between higher levels of apathy and cognitive decline over the following year. This highlights the pervasive nature of apathy and its potential implications for cognitive health in a broader population.

The article titled "Apathy as a Predictor for Conversion From Mild Cognitive Impairment to Dementia: A Systematic Review and Meta-Analysis of Longitudinal Studies" provides a comprehensive examination of the relationship between apathy and the progression from mild cognitive impairment (MCI) to dementia. The systematic review and meta-analysis approach employed by the authors enhances the reliability of the findings by aggregating data from multiple

longitudinal studies, thereby allowing for a more robust analysis of the association between apathy and incident dementia.

The authors conducted a thorough literature search across several reputable databases, including Medline, Embase, Cochrane Library, Epistemonikos, PsychINFO, and CINAHL. This broad search strategy ensures that the review captures a wide range of studies, which is critical for synthesizing evidence on the topic. The inclusion criteria focused on longitudinal studies specifically reporting the association between apathy and dementia, which is pertinent as it underscores the temporal relationship necessary to infer predictive capabilities.

One of the key insights of the article is the identification of apathy as a significant predictor for the conversion from MCI to dementia. The authors provide a detailed analysis of the included studies, highlighting how apathy manifests as a behavioral symptom that may precede cognitive decline. This finding is particularly important as it suggests that apathy could serve as an early warning sign for clinicians, potentially guiding early interventions aimed at delaying or preventing the onset of dementia.

However, while the article presents compelling evidence linking apathy to dementia progression, it is important to note the inherent limitations of meta-analyses. The variability in study designs, sample sizes, and measurement tools for apathy across the included studies could introduce heterogeneity that may affect the overall conclusions. Additionally, the article does not extensively address potential confounding factors that could influence the relationship between apathy and dementia, such as depression or other psychiatric conditions, which are known to overlap with apathy.

Moreover, the authors could have expanded on the implications of their findings for clinical practice and future research. Understanding the mechanisms underlying the relationship between apathy and dementia progression could pave the way for targeted therapeutic strategies. Future studies might benefit from exploring the neurobiological underpinnings of apathy and its potential modifiability through interventions.

The article titled "Prevalence, treatment, and neural correlates of apathy in different forms of dementia: a narrative review" provides a comprehensive overview of apathy within the context of various dementias, emphasizing its multifaceted nature and significant implications for patient care. Apathy is characterized by a reduction in goal-directed behavior and impaired motivation, which can manifest in three distinct phenotypes: emotional-affective, cognitive, and auto-activation apathy. This classification is critical as it underscores the complexity of apathy and suggests that different therapeutic approaches may be required depending on the specific phenotype exhibited by patients.

The authors highlight that apathy is not only prevalent in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease dementia, frontotemporal dementia, and vascular dementia, but its incidence also escalates with disease progression. This correlation raises concerns about the impact of apathy on cognitive decline, as it is associated with a more rapid deterioration in cognitive functions and an increased likelihood of institutionalization. Such findings underscore the need for heightened awareness among clinicians regarding the significance of apathy as a potential early indicator of dementia progression.

Despite the growing recognition of apathy in dementia, the article points out several critical gaps in the current literature. For instance, the authors note the lack of consensus on standardized assessment tools for apathy, which complicates both diagnosis and treatment. Furthermore, the limited exploration of apathy as a primary outcome in clinical studies suggests that this symptom is often overshadowed by other cognitive deficits, leading to potential misdiagnosis and inadequate treatment options. The authors advocate for more focused research on the neurobiological underpinnings of apathy and its treatment, as the existing evidence remains sparse.

The review also emphasizes the profound impact of apathy on the quality of life for both patients and caregivers. By acknowledging the emotional and psychological toll that apathy takes on families and care networks, the authors

highlight the necessity of addressing this symptom not only from a clinical perspective but also in terms of holistic care practices.

CONCLUSION

The literature reviewed presents compelling evidence that apathy is a significant behavioral marker for cognitive decline and an important predictor of incident dementia across various neurodegenerative conditions. Apathy is increasingly recognized not merely as a symptom but as a potential biomarker that can indicate the progression of cognitive impairment, particularly in disorders such as Parkinson's disease (PD), Alzheimer's disease (AD), and frontotemporal dementia (FTD).

The studies reveal that apathy often precedes cognitive decline, with specific research indicating that individuals with PD who exhibit apathy show a more pronounced deterioration in cognitive performance over time (P. Martin et al., 2009). Furthermore, in presymptomatic carriers of genetic mutations linked to FTD, apathy is identified as an early manifestation that correlates with structural brain changes, thus serving as a critical indicator for cognitive deterioration (Malpetti et al., 2010). The prevalence of apathy in AD is particularly concerning, with studies noting that it affects a significant portion of patients and correlates with disease progression, making it a crucial factor for transition from normal cognition to mild cognitive impairment (MCI) and subsequently to AD dementia (L. Teixeira et al., 2011).

The systematic reviews and meta-analyses included in the literature reinforce the notion of apathy as a prodromal syndrome for dementia, highlighting its role in predicting the conversion from MCI to dementia. These reviews emphasize the need for sensitive measures to detect apathy in older adults, as early identification could facilitate timely interventions that may delay cognitive decline.

Moreover, the neurobiological underpinnings of apathy, including its association with frontostriatal degeneration and inflammatory markers, further elucidate its role in cognitive impairment (C. Steffens et al., 2012). The narrative

review on the prevalence, treatment, and neural correlates of apathy underscores the multifaceted nature of this syndrome and the necessity for standardized assessment tools to improve diagnosis and treatment strategies across different forms of dementia (Parrotta et al., 2014).

In conclusion, the literature collectively supports the critical role of apathy as a behavioral marker of cognitive decline and its implications for dementia risk assessment and management. By recognizing and addressing apathy in clinical settings, healthcare providers can enhance patient outcomes and potentially mitigate the progression of cognitive impairment in at-risk populations.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. P. Martin, G., R. McDonald, K., Allsop, D., J. Diggle, P., & Leroi, I., 2009. Apathy as a behavioural marker of cognitive impairment in Parkinson's disease: a longitudinal analysis. ncbi.nlm.nih.gov
2. Malpetti, M., Simon Jones, P., A. Tsvetanov, K., Rittman, T., C. van Swieten, J., Borroni, B., Sanchez-Valle, R., Moreno, F., Laforce, R., Graff, C., Synofzik, M., Galimberti, D., Masellis, M., Carmela Tartaglia, M., Finger, E., Vandenberghe, R., de Mendonça, A., Tagliavini, F., Santana, I., Ducharme, S., R. Butler, C., Gerhard, A., Levin, J., Danek, A., Otto, M., B. Frisoni, G., Ghidoni, R., Sorbi, S., Heller, C., G. Todd, E., Bocchetta, M., M. Cash, D., S. Convery, R., Peakman, G., M. Moore, K., D. Rohrer, J., A. Kievit, R., B. Rowe, J., & FTD Initiative (GENFI), G., 2010. Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. ncbi.nlm.nih.gov

3. L. Teixeira, A., M. Gonzales, M., Cruz de Souza, L., & L. Weisenbach, S., 2011. Revisiting Apathy in Alzheimer's Disease: From Conceptualization to Therapeutic Approaches. ncbi.nlm.nih.gov
4. Fan, Z., Wang, L., Zhang, H., Lv, X., Tu, L., Zhang, M., Zhang, Y., Yan, C., Yu, X., & Wang, H., 2011. Apathy as a Risky Neuropsychiatric Syndrome of Progression From Normal Aging to Mild Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis. ncbi.nlm.nih.gov
5. C. Steffens, D., Fahed, M., J. Manning, K., & Wang, L., 2012. The neurobiology of apathy in depression and neurocognitive impairment in older adults: a review of epidemiological, clinical, neuropsychological and biological research. ncbi.nlm.nih.gov
6. Fresnais, D., B. Humble, M., Bejerot, S., D. Meehan, A., & Fure, B., 2013. Apathy as a Predictor for Conversion From Mild Cognitive Impairment to Dementia: A Systematic Review and Meta-Analysis of Longitudinal Studies. ncbi.nlm.nih.gov
7. Parrotta, I., Cacciatore, S., D'Andrea, F., D'Anna, M., Giancaterino, G., Lazzaro, G., Arcara, G., & Manzo, N., 2014. Prevalence, treatment, and neural correlates of apathy in different forms of dementia: a narrative review. ncbi.nlm.nih.gov